PEXEVA Drug Patent Profile
When do Pexeva patents expire, and when can generic versions of Pexeva launch?
Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA.
The generic ingredient in PEXEVA is paroxetine mesylate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pexeva
A generic version of PEXEVA was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PEXEVA?
- What are the global sales for PEXEVA?
- What is Average Wholesale Price for PEXEVA?
Summary for PEXEVA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 33 |
| Clinical Trials: | 1 |
| Patent Applications: | 224 |
| Drug Prices: | Drug price information for PEXEVA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PEXEVA |
| What excipients (inactive ingredients) are in PEXEVA? | PEXEVA excipients list |
| DailyMed Link: | PEXEVA at DailyMed |
Recent Clinical Trials for PEXEVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sheppard Pratt Health System | N/A |
| Central Michigan University | N/A |
US Patents and Regulatory Information for PEXEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-001 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEXEVA
International Patents for PEXEVA
See the table below for patents covering PEXEVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 200781 | ⤷ Start Trial | |
| Australia | 3108097 | ⤷ Start Trial | |
| Bulgaria | 103980 | ⤷ Start Trial | |
| Bulgaria | 64315 | ⤷ Start Trial | |
| Brazil | 9714787 | ⤷ Start Trial | |
| Canada | 2293247 | COMPOSES 4-PHENYLPIPERIDINE (4-PHENYLPIPERIDINE COMPOUNDS) | ⤷ Start Trial |
| Czech Republic | 295301 | Deriváty 4-fenylpiperidinu, způsob jejich přípravy, jejich použití a lék je obsahující (4-Phenylpiperidine derivatives, process of their preparation, their use and medicament in which the derivatives are comprised) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |



